Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children.
Kimata
H
H
D000287:Administration, Topical; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002019:Bufexamac / Q000008:administration & dosage; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D016106:Methicillin Resistance; D011807:Quinolizines / Q000008:administration & dosage*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D024841:Fluoroquinolones; D011807:Quinolizines; D002019:Bufexamac; C062127:nadifloxacin